2772-5723

Gastro Hep Advances

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1078 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1078 DOIs
2

Deposit reference lists for 259 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact259 DOIs
3

Attach ORCID iDs across 226 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact226 DOIs

DOIs for this ISSN

Showing the top 5 of 1078 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Worldwide Incidence and Mortality of Biliary Tract Cancer (10.1016/j.gastha.2022.04.007)
Abstract ORCID
89.27 60
2 Circadian Rhythms, the Gut Microbiome, and Metabolic Disorde… (10.1016/j.gastha.2021.10.008)
Abstract ORCID
86.62 53
3 Understanding the Changing Landscape of Health Disparities i… (10.1016/j.gastha.2022.12.001)
Abstract ORCID
73.12 28
4 It Is Time for a Simplified Approach to Hepatitis B Eliminat… (10.1016/j.gastha.2022.10.004)
Abstract ORCID
70.75 25
5 Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular… (10.1016/j.gastha.2023.07.012)
Abstract ORCID
68.09 22
6 The Role of Race, Sex, and Age in Circadian Disruption and M… (10.1016/j.gastha.2022.02.015)
Abstract ORCID
63.94 18
7 Examining the Role of Type 2 Inflammation in Eosinophilic Es… (10.1016/j.gastha.2022.05.004)
Abstract ORCID
61.52 16
8 Silymarin for Treating Toxic Liver Disease: International Co… (10.1016/j.gastha.2022.05.006)
Abstract ORCID
58.80 14
9 Evaluation of Protein Kinase cAMP-Activated Catalytic Subuni… (10.1016/j.gastha.2022.11.004)
Abstract ORCID
57.31 13
10 Human Milk Supports Robust Intestinal Organoid Growth, Diffe… (10.1016/j.gastha.2024.07.007)
Abstract ORCID
55.70 12
11 Symptom Scores and pH-Impedance: Secondary Analysis of a Ran… (10.1016/j.gastha.2022.06.004)
Abstract ORCID
53.96 11
12 Risk Prediction of Pancreatic Cancer in Patients With Abnorm… (10.1016/j.gastha.2022.06.008)
Abstract ORCID
53.96 11
13 Treatment Patterns and Survival in Locally Advanced or Metas… (10.1016/j.gastha.2023.01.009)
Abstract ORCID
52.07 10
14 Kombucha-Induced Massive Hepatic Necrosis: A Case Report and… (10.1016/j.gastha.2022.09.014)
Abstract ORCID
50.00 9
15 Advanced Fibrosis in Metabolic Dysfunction-Associated Steato… (10.1016/j.gastha.2023.09.008)
Abstract ORCID
50.00 9
16 Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A L… (10.1016/j.gastha.2024.04.005)
Abstract ORCID
50.00 9
17 Algorithm Development and Early Performance Evaluation of a… (10.1016/j.gastha.2024.05.002)
Abstract ORCID
50.00 9
18 Endoscopic Ultrasound-Guided Liver Biopsy in Clinical Practi… (10.1016/j.gastha.2022.07.007)
Abstract ORCID
47.71 8
19 Comparative Performance of Quantitative and Qualitative Magn… (10.1016/j.gastha.2022.01.003)
Abstract ORCID
45.15 7
20 Master Transcription Regulators and Transcription Factors Re… (10.1016/j.gastha.2022.01.004)
Abstract ORCID
45.15 7
21 Noninvasive, MultiOmic, and Multicompartmental Biomarkers of… (10.1016/j.gastha.2023.01.014)
Abstract ORCID
45.15 7
22 Epidermal Growth Factor Receptor Inhibition With Erlotinib i… (10.1016/j.gastha.2024.01.009)
Abstract ORCID
45.15 7
23 Projected Healthcare System Cost Burden of Metabolic Dysfunc… (10.1016/j.gastha.2024.05.010)
Abstract ORCID
45.15 7
24 Nucleos(t)ide Analog Treatment Discontinuation in Chronic He… (10.1016/j.gastha.2024.08.015)
Abstract ORCID
45.15 7
25 Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as… (10.1016/j.gastha.2024.04.011)
Abstract ORCID
42.25 6
26 Health-Related Quality of Life and Perceived Stigma in Eosin… (10.1016/j.gastha.2024.07.015)
Abstract ORCID
42.25 6
27 Tumor Budding as a Risk Factor for Lymph Node Metastasis and… (10.1016/j.gastha.2025.100713)
Abstract ORCID
42.25 6
28 The Impact of Climate Change, Pollution, and Biodiversity Lo… (10.1016/j.gastha.2024.01.018)
Abstract
41.33 44
29 Farnesoid X Receptor Agonists: A Promising Therapeutic Strat… (10.1016/j.gastha.2023.09.013)
Abstract
40.32 40
30 Racial Differences in Helicobacter pylori Prevalence in the… (10.1016/j.gastha.2022.06.001)
Abstract
40.05 39
31 Artificial Intelligence and Machine Learning: What You Alway… (10.1016/j.gastha.2021.11.001)
Abstract
39.78 38
32 Colorectal Cancer Immunotherapy: State of the Art and Future… (10.1016/j.gastha.2023.09.007)
Abstract
39.49 37
33 Development and Clinical Validation of a Blood Test for Earl… (10.1016/j.gastha.2021.11.004)
Abstract ORCID
38.91 5
34 Study of Acid-related Disorders: Real-world Physician and Pa… (10.1016/j.gastha.2021.12.005)
Abstract ORCID
38.91 5
35 A Case of Eosinophilic Gastroenteritis Remission Achieved St… (10.1016/j.gastha.2022.03.003)
Abstract ORCID
38.91 5
36 Outcomes of Continuation vs Discontinuation of Adalimumab Th… (10.1016/j.gastha.2022.04.009)
Abstract ORCID
38.91 5
37 The Burden of Nonalcoholic Steatohepatitis: A Systematic Rev… (10.1016/j.gastha.2022.06.016)
Abstract ORCID
38.91 5
38 Observational Burden of Illness Study in Patients With Crohn… (10.1016/j.gastha.2023.08.011)
Abstract ORCID
38.91 5
39 Digital Rectal Examination: An Invaluable Clinical Tool (10.1016/j.gastha.2024.03.002)
Abstract References
38.91 5
40 Non-Helicobacter pylori Gastric Microbiome Modulates Proonco… (10.1016/j.gastha.2023.03.010)
Abstract
38.29 33
41 Gastroparesis and Functional Dyspepsia: Spectrum of Gastrodu… (10.1016/j.gastha.2022.10.005)
Abstract
36.56 28
42 Defining and Phenotyping Gastric Abnormalities in Long-Term… (10.1016/j.gastha.2023.08.005)
Abstract
36.18 27
43 Regulatory T Cell (Treg) Cytotoxic T Lymphocyte–associated A… (10.1016/j.gastha.2021.12.012)
Abstract ORCID
34.95 4
44 Substance Use Disorder Is Associated With Alcohol-Associated… (10.1016/j.gastha.2022.02.004)
Abstract ORCID
34.95 4
45 Artificial Intelligence and the Future of Gastroenterology a… (10.1016/j.gastha.2022.02.025)
Abstract
34.95 24
46 Health Care Resource Use and Associated Costs of Cyclic Vomi… (10.1016/j.gastha.2022.06.013)
Abstract
34.95 24
47 Pancreatic Cancer is More Frequently Early Stage at Diagnosi… (10.1016/j.gastha.2022.07.004)
Abstract ORCID
34.95 4
48 The Association of Race, Ethnicity, and Insurance Status Wit… (10.1016/j.gastha.2022.07.016)
Abstract ORCID
34.95 4
49 Patient Preferences for Ulcerative Colitis Treatment in the… (10.1016/j.gastha.2023.10.002)
Abstract ORCID
34.95 4
50 The Roles of Gut Microbiota Metabolites in the Occurrence an… (10.1016/j.gastha.2024.05.012)
Abstract
34.95 24